The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma

National Taiwan University

Status: Active, not recruiting

Conditions: Serum Tumor Markers

Treatments: Diagnostic Test: Met-score

Study type: Observational

Funder types: Other

Identifiers

NCT05576571

202009079DIPB

Details and patient eligibility

About

Patients with liver cancer expected to undergo radiofrequency ablation or transvascular embolization. Relevant tumor markers (AFP and methylation analysis) were performed. The two data are then counted and compared.

Full description

The subjects of this study were patients who were diagnosed with liver cancer by physicians based on AASLD clinical criteria or pathological biopsy.

Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital. Which excludes weakness and inability to cooperate Patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (AFP and methylation analysis). The two data are then counted Compare.

Enrollment: 90 estimated patients

Sex: All

Ages: 20 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients diagnosed with liver cancer by AASLD clinical criteria or pathological sections are planned to receive treatment at National Taiwan University Hospital Liver local treatment such as radiofrequency ablation or transvascular embolization.
2. Be over 20 years old.
3. Under the condition of informed consent, willing to sign the consent form of the subjects.

Exclusion criteria

1. Patients who are weak and unable to cooperate with blood test.
2. Kidney dysfunction, serum creatinine greater than 1.5mg/dl, it is judged that computer tomography or MRI cannot be performed Vibrate the injector.

Trial design

90 participants in 1 patient group

HCC case

Description:

Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital. Which excludes weakness and inability to cooperate Patients with blood test, under the condition of fully informed consent, complete blood test related tumor indicators (AFP and methylation analysis). The two data are then counted Compare.

Treatment:

Diagnostic Test: Met-score